PRESS RELEASE: Meditrina Announces Manufacturing Agreement with Pfizer Centresource (PCS) for Femathina (MPI-674)

MEDITRINA PHARMACEUTICALS, INC. ANNOUNCES EXCLUSIVE GLOBAL MANUFACTURING AGREEMENT WITH PFIZER CENTRESOURCE (PCS) FOR FEMATHINAâ„¢ (MPI-674)

- Advances the Company’s Lead Product Candidate Development Program -

ANN ARBOR, Mich. (September 19, 2007) – Meditrina Pharmaceuticals, Inc., today announced that it is has completed a contract manufacturing agreement for drug product development and active pharmaceutical ingredient (API) supply with a unit of Pfizer CentreSource (PCS), a leading supplier of APIs and dosage form manufacturing, for the Company’s lead product candidate, Femathina™ (MPI-674).  Currently in phase II clinical trials, MPI-674 is an aromatase inhibitor that Meditrina is repurposing for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

“We are delighted to have such a skilled and reputable manufacturing partner for MPI-674,” said Holly Vene, COO and vice president, business development, Meditrina Pharmaceuticals, Inc.  “Securing a high-quality commercial supply chain partner has been a key focus of the organization and represents an important milestone in advancing our product development program.” 

"We look forward to working with Meditrina, a respected and innovative company that is also located in Michigan, a state in which PCS has deep roots,” commented Michael J. Kosko, president, Pfizer CentreSource.  “And we are delighted to be able to contribute our development and manufacturing expertise to the supply of this product."

Terms of the agreement were not disclosed.

About MPI-674
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile.  AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. 

AIs are currently used for the chronic treatment of estrogen-dependent tumors in postmenopausal women and are being investigated in a variety of women’s health conditions.  Meditrina holds the exclusive worldwide rights to patent applications covering the use of AIs in gynecologic indications, including for endometrial thinning prior to hysteroscopic procedures.

About Meditrina Pharmaceuticals, Inc.
Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women’s reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.  By identifying, leveraging and repurposing marketed products and product candidates at advanced stages of development, Meditrina’s novel therapies have the potential to significantly alter the way these women’s health conditions are treated.  For more information about Meditrina Pharmaceuticals, please visit www.meditrina.com.

About Pfizer CentreSource
Pfizer CentreSource (PCS) is a separate operating unit within Pfizer, the world's leading research-based pharmaceutical company, which has extensive capabilities and experience in active pharmaceutical ingredient and dosage form manufacturing.  A globally networked business, PCS markets active pharmaceutical ingredients (APIs), fine chemical intermediates, finished dosage forms and provides analytical and regulatory support.  For more information, contact Pfizer CentreSource at 269-833-5844 or visit www.pfizercentresource.com.

Meditrina Pharmaceuticals, Inc. Forward-Looking Statement Disclaimer
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

Suggested Articles

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.